VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status : Interaction between both genotypes affects dose requirement
- Author
- SCHALEKAMP, T1 ; BRASSE, B. P2 ; ROIJERS, J. F. M2 ; VAN MEEGEN, E3 ; VAN DER MEER, F. J. M4 ; VAN WIJK, E. M2 ; EGBERTS, A. C. G1 2 ; DE BOER, A1
[1] Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, Utrecht, Netherlands
[2] Department of Clinical Pharmacy and Clinical Chemistry and Haematology, TweeSteden Hospital and St. Elisabeth Hospital, Tilburg, Netherlands
[3] Red Cross Anticoagulation Clinic, The Hague, Netherlands
[4] Department of Haematology, Leiden University Medical Centre, Leiden, Netherlands - Source
Clinical pharmacology and therapeutics. 2007, Vol 81, Num 2, pp 185-193, 9 p ; ref : 38 ref
- CODEN
- CLPTAT
- ISSN
- 0009-9236
- Scientific domain
- Pharmacology drugs
- Publisher
- Nature Publishing, New York, NY
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticoagulant Cytochrome P450 Dose Génotype Homme Interaction Isozyme Phenprocoumone Traitement Typage Vitamin-K-epoxide reductase (warfarin-sensitive) Cytochrome P4502C9 Gène CYP2C9 Gène VKORC1 Antivitamine K Enzyme Oxidoreductases
- Keyword (en)
- Anticoagulant Cytochrome P450 Dose Genotype Human Interaction Isozyme Phenprocoumon Treatment Typing Vitamin-K-epoxide reductase (warfarin-sensitive) CYP2C9 gene VKORC1 gene Antivitamin K Enzyme Oxidoreductases
- Keyword (es)
- Anticoagulante Citocromo P450 Dosis Genotipo Hombre Interacción Isozima Fenprocumon Tratamiento Tipificación Vitamin-K-epoxide reductase (warfarin-sensitive) Antivitamina K Enzima Oxidoreductases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments
- Discipline
- General pharmacology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 18560870
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1038/sj.clpt.6100036 
https://dx.doi.org/10.1038/sj.clpt.6100036
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1038\/sj.clpt.6100036\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:130:\"VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status : Interaction between both genotypes affects dose requirement\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Clinical pharmacology and therapeutics\";s:9:\"\u0000*\u0000stitle\";s:21:\"Clin. pharmacol. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"81\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"185\";s:8:\"\u0000*\u0000epage\";s:3:\"193\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-9236\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"SCHALEKAMP\";s:10:\"\u0000*\u0000aufirst\";s:1:\"T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:12:\"BRASSE, B. P\";i:1;s:16:\"ROIJERS, J. F. M\";i:2;s:13:\"VAN MEEGEN, E\";i:3;s:21:\"VAN DER MEER, F. J. M\";i:4;s:14:\"VAN WIJK, E. M\";i:5;s:16:\"EGBERTS, A. C. G\";i:6;s:10:\"DE BOER, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CLPTAT\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:130:\"VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status : Interaction between both genotypes affects dose requirement\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1038\/sj.clpt.6100036\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:130:\"VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status : Interaction between both genotypes affects dose requirement\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Clinical pharmacology and therapeutics\";s:9:\"\u0000*\u0000stitle\";s:21:\"Clin. pharmacol. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"81\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"185\";s:8:\"\u0000*\u0000epage\";s:3:\"193\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-9236\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"SCHALEKAMP\";s:10:\"\u0000*\u0000aufirst\";s:1:\"T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:12:\"BRASSE, B. P\";i:1;s:16:\"ROIJERS, J. F. M\";i:2;s:13:\"VAN MEEGEN, E\";i:3;s:21:\"VAN DER MEER, F. J. M\";i:4;s:14:\"VAN WIJK, E. M\";i:5;s:16:\"EGBERTS, A. C. G\";i:6;s:10:\"DE BOER, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CLPTAT\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:130:\"VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status : Interaction between both genotypes affects dose requirement\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:23:\"10.1038\/sj.clpt.6100036\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1038\/sj.clpt.6100036\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:130:\"VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status : Interaction between both genotypes affects dose requirement\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Clinical pharmacology and therapeutics\";s:9:\"\u0000*\u0000stitle\";s:21:\"Clin. pharmacol. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"81\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"185\";s:8:\"\u0000*\u0000epage\";s:3:\"193\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-9236\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"SCHALEKAMP\";s:10:\"\u0000*\u0000aufirst\";s:1:\"T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:12:\"BRASSE, B. P\";i:1;s:16:\"ROIJERS, J. F. M\";i:2;s:13:\"VAN MEEGEN, E\";i:3;s:21:\"VAN DER MEER, F. J. M\";i:4;s:14:\"VAN WIJK, E. M\";i:5;s:16:\"EGBERTS, A. C. G\";i:6;s:10:\"DE BOER, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CLPTAT\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:130:\"VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status : Interaction between both genotypes affects dose requirement\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1038\/sj.clpt.6100036\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:130:\"VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status : Interaction between both genotypes affects dose requirement\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Clinical pharmacology and therapeutics\";s:9:\"\u0000*\u0000stitle\";s:21:\"Clin. pharmacol. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"81\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"185\";s:8:\"\u0000*\u0000epage\";s:3:\"193\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-9236\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"SCHALEKAMP\";s:10:\"\u0000*\u0000aufirst\";s:1:\"T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:12:\"BRASSE, B. P\";i:1;s:16:\"ROIJERS, J. F. M\";i:2;s:13:\"VAN MEEGEN, E\";i:3;s:21:\"VAN DER MEER, F. J. M\";i:4;s:14:\"VAN WIJK, E. M\";i:5;s:16:\"EGBERTS, A. C. G\";i:6;s:10:\"DE BOER, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CLPTAT\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:130:\"VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status : Interaction between both genotypes affects dose requirement\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1038\/sj.clpt.6100036\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:130:\"VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status : Interaction between both genotypes affects dose requirement\";s:9:\"\u0000*\u0000jtitle\";s:38:\"Clinical pharmacology and therapeutics\";s:9:\"\u0000*\u0000stitle\";s:21:\"Clin. pharmacol. ther\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"81\";s:8:\"\u0000*\u0000issue\";s:1:\"2\";s:8:\"\u0000*\u0000spage\";s:3:\"185\";s:8:\"\u0000*\u0000epage\";s:3:\"193\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0009-9236\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"SCHALEKAMP\";s:10:\"\u0000*\u0000aufirst\";s:1:\"T\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:12:\"BRASSE, B. P\";i:1;s:16:\"ROIJERS, J. F. M\";i:2;s:13:\"VAN MEEGEN, E\";i:3;s:21:\"VAN DER MEER, F. J. M\";i:4;s:14:\"VAN WIJK, E. M\";i:5;s:16:\"EGBERTS, A. C. G\";i:6;s:10:\"DE BOER, A\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CLPTAT\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:130:\"VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status : Interaction between both genotypes affects dose requirement\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:17:\"Nature Publishing\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
